(Q57738540)

7 January 2021

Depression: cost-of-illness studies in the international literature, a review

1 reference

7 January 2021

A double-blind comparison of escitalopram and paroxetine in the long-term treatment of generalized anxiety disorder

1 reference

7 January 2021

Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients

1 reference

7 January 2021

The S-enantiomer of R,S-citalopram, increases inhibitor binding to the human serotonin transporter by an allosteric mechanism. Comparison with other serotonin transporter inhibitors

1 reference

7 January 2021

How to improve the risk-benefit ratio of antidepressants.

1 reference

7 January 2021

A cost-effectiveness model of escitalopram, citalopram,and venlafaxine as first-line treatment for major depressive disorder in Belgium

1 reference

7 January 2021

Evaluation of the cost effectiveness of escitalopram versus venlafaxine XR in major depressive disorder.

1 reference

7 January 2021

A pharmacoeconomic evaluation of escitalopram, a new selective serotonin reuptake inhibitor. Comparison of cost-effectiveness between escitalopram, citalopram, fluoxetine, and venlafaxine for the treatment of depression in Norway

1 reference

7 January 2021

Treatment of generalized anxiety disorder with escitalopram: pooled results from double-blind, placebo-controlled trials

1 reference

7 January 2021

Efficacy comparison of escitalopram and citalopram in the treatment of major depressive disorder: pooled analysis of placebo-controlled trials.

1 reference

7 January 2021

Phase IV research by pharmaceutical companies

1 reference

7 January 2021

Cost-effectiveness analysis of escitalopram: a new SSRI in the first-line treatment of major depressive disorder in Austria

1 reference

7 January 2021

Cost-effectiveness of escitalopram versus citalopram in the treatment of severe depression

1 reference

7 January 2021

Escitalopram in the treatment of social anxiety disorder: randomised, placebo-controlled, flexible-dosage study

1 reference

7 January 2021

Onset of action of escitalopram compared with other antidepressants: results of a pooled analysis

1 reference

7 January 2021

The effects of chronic medical conditions on work loss and work cutback.

1 reference

7 January 2021

Escitalopram (10-20 mg/day) is effective and well tolerated in a placebo-controlled study in depression in primary care

1 reference

7 January 2021

Efficacy of escitalopram in patients with severe depression: a pooled analysis

1 reference

7 January 2021

Prospective, multicentre, randomized, double-blind study of the efficacy of escitalopram versus citalopram in outpatient treatment of major depressive disorder

1 reference

7 January 2021

Escitalopram in Seasonal Affective Disorder: Results of an Open Trial

1 reference

7 January 2021

Escitalopram continuation treatment prevents relapse of depressive episodes

1 reference

7 January 2021

Escitalopram in clinical practice: results of an open-label trial in a naturalistic setting

1 reference

7 January 2021

Escitalopram in the treatment of panic disorder: a randomized, double-blind, placebo-controlled trial.

1 reference

7 January 2021

A pharmacoeconomic evaluation of escitalopram versus citalopram in the treatment of severe depression in the United Kingdom

1 reference

7 January 2021

A probabilistic cost-effectiveness analysis of escitalopram, generic citalopram and venlafaxine as a first-line treatment of major depressive disorder in the UK.

1 reference

7 January 2021